6-Chloro-2-methyl-2H-indazol-5-amine CAS 1893125-36-4 Purity >98.0% (LCMS) Ensitrelvir (S-217622) Intermediate COVID-19

Short Description:

Name: 6-Chloro-2-methyl-2H-indazol-5-amine

CAS: 1893125-36-4

Purity: >98.0% (LCMS)

Appearance: Light Brown to Gray Solid Powder

Intermediate of Ensitrelvir (S-217622), COVID-19

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Commercial Supply Ensitrelvir (S-217622) Intermediates:
S-Ethylisothiourea Hydrobromide CAS 1071-37-0
2,4,5-Trifluorobenzyl Bromide CAS 157911-56-3
Trimethyloxonium Tetrafluoroborate CAS 420-37-1
6-Chloro-2-methyl-2H-indazol-5-amine CAS 1893125-36-4
3-(Chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride CAS 135206-76-7
1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethylethyl)-6-(ethylthio)- CAS 1360105-53-8

Chemical Properties:

Chemical Name	6-Chloro-2-methyl-2H-indazol-5-amine
CAS Number	1893125-36-4
CAT Number	RF-PI1506
Stock Status	In Stock
Molecular Formula	C8H8ClN3
Molecular Weight	181.62
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Light Brown to Gray Solid Powder
Purity / Analysis Method	>98.0% (LCMS)
1 H NMR Spectrum	Consistent With Structure
LCMS	Consistent With Structure
Loss on Drying	≤1.00%
Total Impurities	<2.00%
Test Standard	Enterprise Standard
Usage	Intermediate of Ensitrelvir (S-217622), COVID-19

Package & Storage:

Package: Bottle, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

6-Chloro-2-methyl-2H-indazol-5-amine (CAS: 1893125-36-4) is an intermediate of Ensitrelvir (S-217622). Ensitrelvir by Shionogi & Co. is a highly effective antiviral drug that works just as well as Pfizer's Paxlovid. Oral Xocova (Ensitrelvir), which has the same mechanism of action as Pfizer’s Paxlovid (Nirmatrelvir+Ritonavir), differs in that it only needs to be taken once a day, while the therapeutic effectiveness of ensitrelvir does not seem to be inferior to Paxlovid. As a reminder, Nirmatrelvir is administered twice daily, together with the booster represented by Ritonavir. Ensitrelvir became the first Japanese domestic pill to treat COVID-19, third to be regulatorally approved in Japan; in February 2022.